Abbonarsi

Endoscopic full-thickness resection for early colorectal cancer - 17/05/19

Doi : 10.1016/j.gie.2018.12.025 
Armin Kuellmer, MD 1, , Julius Mueller 1, , Karel Caca, MD 2, Patrick Aepli, MD 3, David Albers, MD 4, Brigitte Schumacher, MD 4, Anne Glitsch, MD 5, Claus Schäfer 6, Ingo Wallstabe, MD 7, Christopher Hofmann, MD 8, Andreas Erhardt 9, Benjamin Meier, MD 2, Dominik Bettinger, MD 1, Robert Thimme, MD 1, Arthur Schmidt, MD 1,
the

FTRD study group

1 Department of Medicine II, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg 
2 Department of Gastroenterology and Oncology, Klinikum Ludwigsburg, Ludwigsburg, Germany 
3 Gastroenterology and Hepatology Unit, Luzerner Kantonsspital, Lucerne, Switzerland 
4 Department of Gastroenterology, Elisabeth-Krankenhaus Essen, Teaching Hospital of the University of Duisburg-Essen, Essen 
5 Department of Surgery, University Hospital Greifswald, Greifswald 
6 Medical Clinic II, Klinikum Neumarkt, Neumarkt 
7 Department for Gastroenterology, Hepatology, Diabetology und Endocrinology, Klinikum St. Georg gGmbH, Leipzig 
8 Department for Gastroenterology, Katholisches Klinikum Mainz, Mainz 
9 Department for Gastroenterology, Hepatology und Diabetology, Petrus-Krankenhaus, Wuppertal, Germany 

Reprint requests: Arthur Schmidt, Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany.Department of Medicine IIMedical CenterFaculty of MedicineUniversity of FreiburgHugstetter Strasse 55Freiburg79106Germany

Abstract

Background and Aims

Current international guidelines recommend endoscopic resection for T1 colorectal cancer (CRC) with low-risk histology features and oncologic resection for those at high risk of lymphatic metastasis. Exact risk stratification is therefore crucial to avoid under-treatment as well as over-treatment. Endoscopic full-thickness resection (EFTR) has shown to be effective for treatment of non-lifting benign lesions. In this multicenter, retrospective study we aimed to evaluate efficacy, safety, and clinical value of EFTR for early CRC.

Methods

Records of 1234 patients undergoing EFTR for various indications at 96 centers were screened for eligibility. A total of 156 patients with histologic evidence of adenocarcinoma were identified. This cohort included 64 cases undergoing EFTR after incomplete resection of a malignant polyp (group 1) and 92 non-lifting lesions (group 2). Endpoints of the study were: technical success, R0-resection, adverse events, and successful discrimination of high-risk versus low-risk tumors.

Results

Technical success was achieved in 144 out of 156 (92.3%). Mean procedural time was 42 minutes. R0 resection was achieved in 112 of 156 (71.8%). Subgroup analysis showed a R0 resection rate of 87.5% in Group 1 and 60.9% in Group 2 (P < .001). Severe procedure-related adverse events were recorded in 3.9% of patients. Discrimination between high-risk versus low-risk tumor was successful in 155 of 156 cases (99.3%). In Group 1, 84.1% were identified as low-risk lesions, whereas 16.3% in group 2 had low-risk features. In total, 53 patients (34%) underwent oncologic resection due to high-risk features whereas 98 patients (62%) were followed endoscopically.

Conclusions

In early colorectal cancer, EFTR is technically feasible and safe. It allows exact histological risk stratification and can avoid surgery for low-risk lesions. Prospective studies are required to further define indications for EFTR in malignant colorectal lesions and to evaluate long-term outcome.

Il testo completo di questo articolo è disponibile in PDF.

Graphical abstract




Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : CRC, EFTR, ESD, FTRD, R0, T1


Mappa


 DISCLOSURE: K. Caca received lecture fees and study grants from Ovesco Endoscopy. A. Schmidt received lecture fees from Ovesco Endoscopy. All other authors disclosed no financial relationships relevant to this publication.


© 2019  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 89 - N° 6

P. 1180 - giugno 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • ERCP and elective cholecystectomy are safe in pregnant patients with acute biliary pancreatitis
  • Richard Robbins, Waqar A. Qureshi
| Articolo seguente Articolo seguente
  • Endoscopic full-thickness resection for invasive colorectal neoplasia: Hype or here to stay?
  • Neal Shahidi, Michael J. Bourke

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.